Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer. Issue 5 (May 2022) - Makker, Vicky
Abstract : (Abstracted from N Engl J Med 2022;386:437–448) Little consensus exists on optimal treatment for advanced or recurrent endometrial cancer after disease progression with platinum-based chemotherapy. Lenvatinib is a multitargeted tyrosine kinase inhibitor that as a single agent has demonstrated limited efficacy as second-line treatment of recurrent endometrial carcinoma.